[1. Gutierrez MI, Siraj AK, Khaled H, Koon N, El-Rifai W, Bhatia K. CpG island methylation in Schistosomaand non-Schistosoma-associated bladder cancer. Mod Pathol. 2004; 17:1268-74.10.1038/modpathol.3800177]Open DOISearch in Google Scholar
[2. National Cancer Institute registry. The national cancer registry newsletter, Ministry of Health and Population, Egypt. 2002.]Search in Google Scholar
[3. Kitamura H, Tsukamoto T. Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol. 2006; 11:28-37.10.1007/s10147-006-0552-y]Open DOISearch in Google Scholar
[4. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol. 2002; 41: 284-9.10.1016/S0302-2838(02)00006-4]Open DOISearch in Google Scholar
[5. Eissa S, Labib RA, Swellam M, Bassiony M, Tash FM, Al-Zayat TM. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol. 2007; 52:1388-97a.10.1016/j.eururo.2007.04.00617466450]Open DOISearch in Google Scholar
[6. Eissa S, Salem AM, Zohny SF, Hegazy MG. The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology. Cancer Biomarkers. 2007; 3:275-80b.10.3233/CBM-2007-3601]Search in Google Scholar
[7. Eissa S, Swellam M, Labib RA, Mansour A, El-Malt O, Tash FM. Detection of telomerase in urine by three methods: evaluation of diagnostic accuracy of bladder cancer. J Urol. 2007; 178:1068-72c.10.1016/j.juro.2007.05.00617644139]Search in Google Scholar
[8. Eissa S, Zohny SF, Swellam M, Mahmoud MH, El- Zayat TM, Salem AM. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer. Clin Biochem. 2008; 41:1335-41.10.1016/j.clinbiochem.2008.08.08518804101]Search in Google Scholar
[9. Eissa S, Swellam M, Labib RA, El-Zayat T, El Ahmady O. A panel of angiogenic factors for early bladder cancer detection: enzyme immunoassay and Western blot. J Urol. 2009; 181:1353-60.10.1016/j.juro.2008.10.10219185322]Search in Google Scholar
[10. Eissa S, Shabayek MI, Ismail MF, El-Allawy RM, Hamdy MA. Diagnostic evaluation of apoptosis inhibitory gene and tissue inhibitor matrix metalloproteinase-2 in patients with bladder cancer. IUBMB Life. 2010; 62:394-9a.10.1002/iub.32520408180]Search in Google Scholar
[11. Eissa S, Swellam M, Shehata H, El-Khouly IM, El- Zayat T, El-Ahmady O. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol. 2010; 183:493-8b.10.1016/j.juro.2009.10.02420006858]Search in Google Scholar
[12. Eissa S, Zohny SF, Zekri AR, El-Zayat TM, Maher AM. Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol. 2010; 27:1286-91c.10.1007/s12032-009-9375-9]Open DOISearch in Google Scholar
[13. Eissa S, Swellam M, EL-Khouly IM, Kassim SK, Shehata H, et al. Aberrant methylation of RARb2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer. Cancer Epid Biomark Prev. 2011; 20:1657-64.10.1158/1055-9965.EPI-11-0237]Search in Google Scholar
[14. J Parker, PE Spiess. Current and emerging bladder cancer urinary biomarkers. Science World J. 2011; 11: 1103-12.10.1100/tsw.2011.104]Open DOISearch in Google Scholar
[15. JA Karam, Y Lotan, SF Shariat. Bladder Cancer screening and future directions in urine-based markers for bladder urothelial carcinoma. Lab Med. 2007; 38: 116-20.10.1309/FG6FGPRLDKU3FFP4]Open DOISearch in Google Scholar
[16. Perabo FG, Kamp S, Schmidt D, Lindner H, Steiner G, Mattes RH, et al. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Brit J Cancer. 2001; 84:1330-8.10.1054/bjoc.2001.1808]Open DOISearch in Google Scholar
[17. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, et al. Soluble fas-a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer. 2006; 106:1701-7.10.1002/cncr.21795]Open DOISearch in Google Scholar
[18. American Joint Committee on Cancer (AJCC), Cancer staging manual. Philadelphia, Pa: Lippincott, Pa-Raven Publishers, 5th ed.; 1997.]Search in Google Scholar
[19. Sobin LH, Wittkind CH. UICC TNM classification of malignant tumors, 5th ed., New York: Wiley Liss; 1997. p. 187.]Search in Google Scholar
[20. Papanicolaou GN, Marshall VF. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science. 1945; 101:519.10.1126/science.101.2629.519]Open DOISearch in Google Scholar
[21. Gui M, Idris MA, Shi YE, Muhling A, Ruppel A. Reactivity of Schistosoma japonicum and S. mansoni antigen preparations in indirect haemagglutination (IHA) with sera of patients with homologous and heterogonous schistosomiasis. Ann Trop Med Parasitol. 1991; 85:599-604.10.1080/00034983.1991.11812615]Open DOISearch in Google Scholar
[22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54.10.1016/0003-2697(76)90527-3]Search in Google Scholar
[23. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiol. 1982; 143:29-36.10.1148/radiology.143.1.70637477063747]Search in Google Scholar
[24. Eissa S, Ahmed MI, Said H, Zaghlool A, El-Ahmady O. Cell cycle regulators in bladder cancer: relationship to schistosomiasis. IUBMB Life. 2004; 56:557-64.10.1080/15216540400013903]Open DOISearch in Google Scholar
[25. Sanchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megias J, Mira A, et al. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem. 1999; 45:1944-8.10.1093/clinchem/45.11.1944]Search in Google Scholar
[26. Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fasmolecule are produced by alternative splicing. J Immunol. 1995; 154: 2706-13.10.4049/jimmunol.154.6.2706]Search in Google Scholar
[27. Liu C, Cheng J, Mountz J. Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. J Biochem. 1995; 310: 957-63.10.1042/bj3100957]Search in Google Scholar
[28. Cheng J, Zhou T, Liu C. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263:1759-62.10.1126/science.7510905]Search in Google Scholar
[29. Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, et al. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene. 1995; 10: 1157-64.]Search in Google Scholar
[30. Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesener TG, Bartos DP. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett. 1995; 94:1-8.10.1016/0304-3835(95)03834-J]Open DOISearch in Google Scholar
[31. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas (APO-1/CD95) ligand: Implication for tumor immune escape. Science. 1996; 274:1363-6.10.1126/science.274.5291.1363]Search in Google Scholar
[32. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M. Fas ligand is present in tumors of the Ewing’s sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol. 1998; 153:1947-56.10.1016/S0002-9440(10)65708-2]Search in Google Scholar
[33. Boroumand-Noughabi S, Sima HR, Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, Hosseinnezhad H, et al. Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer. 2010; 10:275-9.10.1186/1471-2407-10-275290647820534173]Open DOISearch in Google Scholar
[34. Konety BR. Molecular markers in bladder cancer: a critical appraisal. Urol Oncol. 2006; 24:326-37.10.1016/j.urolonc.2005.11.02316818187]Open DOISearch in Google Scholar